<a href="https://laohu8.com/S/TELO">Telomir Pharmaceuticals</a> Announces Promising Preclinical Results for Telomir-1 in Reversing Gene Silencing in Prostate Cancer Models
Telomir Pharmaceuticals Inc. has announced preclinical results for its lead candidate, Telomir-1, in a study involving PC3 human prostate cancer cells. The study demonstrated that Telomir-1 effectively reverses epigenetic silencing by DNA methylation of the STAT1 gene, a key tumor suppressor and immune response regulator. Compared to Paclitaxel and Rapamycin, Telomir-1 showed stronger epigenetic effects in aggressive prostate cancer models. The company is conducting further research to evaluate Telomir-1 across various therapeutic areas, including oncology, Wilson's disease, and age-related macular degeneration, with plans to announce its initial IND indication at a future date. These findings were reported on July 17, 2025, indicating that the results have already been presented.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Telomir Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001641172-25-020042), on July 17, 2025, and is solely responsible for the information contained therein.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。